Toxicology Capabilities: From Discovery to IND

CBI offers a complete program of preclinical research services to support a range of your toxicology requirements. We have experience with early
assessment of new molecules including single dose, multiple dose and targeted studies, as well as directed or investigative toxicology, and  IND enabling toxicology programs.

August 2017

Dermal Pharmacology and Toxicology at CBI

Check out our latest updates on our pharmacology models and toxicology capabilities in dermatology.

July 2017

Otic and Auditory Studies at CBI

Comparative Biosciences continues to evolve with niche and specialty pre­clinical, IND enabling GLP or non-­GLP otic and auditory toxicology, efficacy, pharmacokinetics/pharmacodynamics in relevant animal species.

Otic Capabilities

June 2017

See you at ARVO 2017!

CBI will be attending the ARVO annual meeting in Baltimore, MD this year. Please contact our business development team to set up a meeting about your upcoming research needs!

May 2017

Dermatology Capabilities

As the largest organ in the human body, skin plays a vital role in overall health and well-being. With over 20 years of experience, Comparative Biosciences has an arsenal of innovative and validated pharmacological models for dermatological therapeutics.

April 2017

Hyperoxygenation Models at CBI

Clinical indications caused by neonatal hyperoxygenation such as bronchopulmonary fibrosis and retinopathy of prematurity have created an unmet medical need for therapeutic treatments. Comparative Biosciences has multiple robust and validated methods, ready to advance your therapeutic development.

March 2017

Visit Us at SOT

CBI will be attending SOT for our 20th year! Stop by booth #1932 and speak to our expert team about your upcoming preclinical research needs! Look for our poster at the show! Our very own Dr. Laine Ooi will be presenting a poster for our hyperoxia-induced pulmonary dysplasia model.

February 2017

Ocular Toxicology Services

Whatever your ocular study needs, Comparative Biosciences has the answer. With over 20 years of proficiency in the preclinical sphere, we have experience and expertise that you can count on.

Ocular Toxicology | Ocular Pharmacokinetics

January 2017

Comparative Biosciences’ 20th Anniversary

CBI was founded in 1996 by three partners in Santa Clara, CA. We conducted our first GLP study in 1997 and later expanded to our state-of-the-art purpose built facilities in Sunnyvale, CA. Our initial focus involved specialty services, and we continue this dedication 20 years later. This month we are celebrating our 20th anniversary.

August 2016

Diabetic Retinopathy Model

CBI has been helping our Sponsors with developing ocular therapies for 20 years. CBI’s experience and our Sponsors’ innovations are leading to new therapies and clinical trials to advance treatment of ocular diseases.

July 2016

Gene Therapy

Comparative Biosciences is your resource for preclinical Ocular Gene Therapy and Regenerative Medicine Studies.

Ocular Toxicology StudiesOcular Gene Therapy and Regenerative Medicine Studies

June 2016

Focusing on Oncology Studies

CBI has evaluated many potential anti-cancer compounds, our in-house expertise allows us to optimally design studies that provide critical pre-clinical efficacy data. Our custom study plans meet your research needs and prepare you for regulatory submission.

Oncology StudiesIVIS Imaging

January 2016

New Products in Imaging Capabilities

CBI is proud to announce expanded capabilities in imaging to support discovery, exploratory, pharmacology and toxicology studies. We are able to provide the following new imaging capabilities to support your in-vivo preclinical studies: Dermal Fibrosis, LDI (Laser Doppler Instrument), OCT Optical Coherence Tomography), IVS Imaging and PET Scanning, MRI, Digital Radiology, CT and MicroCT

Dermal FibrosisLDI (Laser Doppler Instrument) | OCT (Optical Coherence Tomography) | IVIS Imaging

November 2015

NIH Expo and Grant Support

Visit us at the NIH research festival exhibit in Bethesda, MD, booth #1013. We are also continuing with grant support, from letters of support to collaboration and good faith pricing. Let’s partner together.

September 2015

Oxygen Induced Retinopathy

The most popular model to study abnormal angiogenesis in the retina is the oxygen-induced retinopathy (OIR) model in mice.
Ocular StudiesOCT Studies

August 2015

Using Optical Coherence Tomography (OCT) in Ocular Studies

Optical Coherence Tomography, or “OCT” is a technique for obtaining sub-surface images of translucent or opaque materials at a resolution equivalent to a low-power microscope. It reveals or detects subtle changes, particularly in the eye, that are not visible by other means such as with slit lamp biomicroscopy or funduscopy.
Watch the OCT Demonstration Video
Ocular StudiesAntibacterial Research and Consulting | OCT Studies

July 2015

In situ Hybridization

In situ hybridization (ISH) is a technique used to detect and localize the precesnce or absence of a specific genetic sequence in tissue using a probe with a complementary polynucleotide sequence.
Comparative Biosciences, Inc. offers both fluprescent (FISH) and chromogenic (CISH) is situ hybridization assays.
In Situ Hybridization StudiesHistopathology Studies

June 2015

Xenograft Studies

Xenografts of human tumor tissue into laboratory animal species provide a more accurate model of tour growth and activity administered drugs than in vitro studies. Comparative Biosciences, Inc. offers in vivo xenograft services to conduct drug development for oncology, playing a major role in development of new anti-cancer medicines and therapies.
Xenograft StudiesHistological | Antibacterial Research & Consulting

March 2015

Pre-clinical Studies in Atherosclerosis

Atherosclerosis is present in nearly 52% of americans and represents a huge unmet medical need. It occurs when fat, cholesterol and other substances build up in the walls of arteries and form hard structures called plaques. For companies investigating this disease and its associated symptoms, Comparative Biosciences, Inc. offers efficacy models and studies.C
Contact us for more information on Atherosclerosis studies.
Pharmacology Atherosclerosis Studies | Antibacterial Research & Consulting

February 2015

Investigational New Drug Application Approved

Congratulations to all of our clients and colleagues who have launched successful INDS this past year! Comparative Biosciences, Inc. leader in stem cell pharmacology and GLP Toxicology congratulates our friends and colleagues on their IND successes in 2014, Viacyte, Xeris Pharmaceuticals, Celdara Medical and UCSD.

Contact us to discuss your complex IND needs.ust completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Pharmacology | Stem Cell Research | Antibacterial Research & Consulting

January 2015

Optimal Preclinical Research

Mini-pigs are being used for toxicology and for a wide variety of pharmacology modeling. Comparative Biosciences, Inc. just completed a long term ocular implant, and a long term dermal toxicity as well as numerous burn studies.
Optical Coherence Tomography (OCT) | Thermal Burn Modeling | Antibacterial Research & Consulting

December 2014

DermalOCT and Corneal Study

CBI Dermal OCT Scanning is used in our biomedical research, pharmacology and toxicology, including GLP studies. Our system enables new research opportunities. Applications include Ocular, Skin Models, Xenografts, Rodent Ears, and Tissue Engineering.
Optical Coherence Tomography (OCT) | Stem Cell ResearchAntibacterial Research & Consulting

November 2014

Histopathology

CBI provides contract histology, immunohistochemistry, and pathology services to the biopharmaceutical industry. Whether preparing a single biopsy, a complex histomorphometry study or a complete carcinogenicity study, CBI offers high quality slide preparation, pathological evaluation, and reporting in a timely and cost effective manner. Histopathology is clearly one of the most important tools for assessment of drug efficacy and activity.
Histology Laboratory Capabilities | ImmunohistochemistryPathology

October 2014

New Hope for Diabetes Patients

CBI is the industry leader in conducting difficult and complicated IND enabling and research studies with Stem Cells and Stem-Cell Device combination studies. We have conducted these complex  studies in multiple species and for durations exceeding 1.5 years.
Stem Cell Research | Pharmacology | Antibacterial Research and Consulting

September 2014

Melanin Associated Antigen

CBI is offering for the month of September/October MAA Ocular INFLAMMATION modeling in rats that recapitulates the human disease of Anterior Uveitis.

September 2014

Ocular Toxicology Studies

CBI offers both exploratory proof-of-concept toxicity and tolerability studies and complete preclinical studies. We are also offering OCT intraocular assessments.

August 2014

Burns, Wound Healing and Fibrosis

CBI is developing the models to test the therapeutics that could accelerate the wound healing process. Learn more about our thermal burn modeling services and are Dermal Pharmacology and Efficacy Studies.

June 2014

Ocular Research and Toxicology

CBI provides a wrap-up from ARVO and is now offering OCT intraocular assessments as well as IOP, ERG and angiography.

May 2014

Ophthalmology

CBI provides exploratory/proof-of-concept, GLP toxicology, pharmacokinetics, in vivo animal models, pharmacology, and histopathalogy/immunohistochemistry related to the eye. We are now also offering Optical Coherence Tomography (OCT) for research and toxicology studies. We will be exhibiting at The Association for Research in Vision and Ophthalmology (ARVO) next week, May 4-8, 2014 at booth #338, please stop by.

April 2014

Toxicology

CBI offers a complete program of preclinical research services to support a range of toxicology including: Acute, Subacute and Chronic Toxicity Studies-IND Enabling, Discovery and early Toxicology, Investigative, Ocular, Otic and Dermal Toxicology, Stem Cell Toxicology and many more. We also have a variety of special equipment and capabilities to supplement our regular toxicology.

March 2014

Otolaryngology Research

CBI’s unique experience in preclinical contract otic studies and state-of-the-art facilities, we have the skill and expertise to accelerate new ear drugs from discover y through the drug development process to regulatory submission.

February 2014

Bacterial Infection Modeling

CBI offers a range of infection modeling for the purposes of identification of novel anti-infective agents, particularly MRSA, vancomycin-resistant staph, and gram positive organisms.

February 2014

Heymann Nephritis

Immune-mediated FX-1A-induced glomerular nephritis in rats is an excellent translational model of immune mediated membranous glomerular nephritis in humans.

January 2014

Dexmedetomidine Anesthesia

This research concerned the neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains. In this study, the effects of dexmedetomidine anesthesia was compared to ketamine anesthesia.

January 2014

Histopathology
November 2013

Optical Coherence Tomography
September 2013

Otic Toxicology Studies
August 2013

Thermal Burn Modeling
July 2013

Introducing Optical Coherence Tomography (OCT)
June 2013

FDA New Guidance on Biosimilars
April 2012

Laser-induced Choroidal Neovascularization Model in Rabbits
January 2012

Political Activities of the Major Animal Rights Organizations
October 2011

Models of MS: EAE Models in Mice
September 2011

Over the Past 6 Years, the USDA has Spent over $115M in Animal Welfare Enforcement
June 2011

Laser-induced Choroidal Neovascularization Model in Rabbits
May 2011

2011 SOT Convention
March 2011

Is the Venture Funding Drought Finally Over?
February 2011

What Does it Cost an Organization to Maintain USDA and OLAW Compliance?
January 2011

Toxicology Capabilities at Comparative Biosciences
August 2009

Space Available for Rent at CBI
August 2009

Complement Depletion with Humanized Cobra Venom Factor Reduces Tissue Damage in a Mouse Model for Age-Related Macular Degeneration
August 2009

Antibody Cross-Reactivity Studies at Comparative Biosciences
June 2009

Tissue Cross-Reactivity Studies
June 2009

Stem Cell Research and the Capabilities at CBI
March 2009

CT Scanning at CBI
March 2009